WO2001045727A3 - Stabilized veterinary compositions comprising more than one antiviral agent - Google Patents

Stabilized veterinary compositions comprising more than one antiviral agent Download PDF

Info

Publication number
WO2001045727A3
WO2001045727A3 PCT/EP2000/013017 EP0013017W WO0145727A3 WO 2001045727 A3 WO2001045727 A3 WO 2001045727A3 EP 0013017 W EP0013017 W EP 0013017W WO 0145727 A3 WO0145727 A3 WO 0145727A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
antiviral agent
stabilized
ribavirin
poultry
Prior art date
Application number
PCT/EP2000/013017
Other languages
French (fr)
Other versions
WO2001045727A2 (en
Inventor
A Abdul Rahman Shoa
El-Banna Hossny
Da As Kefah
Original Assignee
New Pharma Res Sweden Ab
A Abdul Rahman Shoa
Hossny El Banna
Da As Kefah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Pharma Res Sweden Ab, A Abdul Rahman Shoa, Hossny El Banna, Da As Kefah filed Critical New Pharma Res Sweden Ab
Priority to EP00983353A priority Critical patent/EP1239923A2/en
Priority to AU20121/01A priority patent/AU2012101A/en
Publication of WO2001045727A2 publication Critical patent/WO2001045727A2/en
Publication of WO2001045727A3 publication Critical patent/WO2001045727A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Compositions for the prophylactic and/or therapeutic treatment of viral diseases, preferably in poultry, comprising as essential active ingredients ribavirin and at least another antiviral agent or active chemical derivatives thereof and a stabilizing agent. Optionally, the compositions further comprise one or more antibiotics of the quinolone type, vitamins and/or preservatives. The compositions are stable upon storage in the form in which they are intended to be administered to poultry, i.e. by injection, orally or by spray. A combined therapy with vaccine or a combination with antibiotics is also possible. The invention concerns also the combined use of ribavirin and other antiviral agents for the treatment of animal viral diseases.
PCT/EP2000/013017 1999-12-20 2000-12-20 Stabilized veterinary compositions comprising more than one antiviral agent WO2001045727A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00983353A EP1239923A2 (en) 1999-12-20 2000-12-20 Stabilized veterinary compositions comprising more than one antiviral agent
AU20121/01A AU2012101A (en) 1999-12-20 2000-12-20 Veterinary compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99125414.5 1999-12-20
EP99125414 1999-12-20

Publications (2)

Publication Number Publication Date
WO2001045727A2 WO2001045727A2 (en) 2001-06-28
WO2001045727A3 true WO2001045727A3 (en) 2002-06-06

Family

ID=8239666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/013017 WO2001045727A2 (en) 1999-12-20 2000-12-20 Stabilized veterinary compositions comprising more than one antiviral agent

Country Status (3)

Country Link
EP (1) EP1239923A2 (en)
AU (1) AU2012101A (en)
WO (1) WO2001045727A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
CN105021756B (en) * 2015-07-01 2017-03-01 山东世通检测评价技术服务有限公司 Amantadine, rimantadine, ribavirin, the multi-joint detection method of Moroxydine residual in a kind of fowl egg
EP3600555A4 (en) * 2017-05-01 2020-10-28 Iraj E. Kiani Anti-viral compositions and method
CN109431981B (en) * 2018-11-26 2020-02-14 天津市中升挑战生物科技有限公司 Enrofloxacin injection and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
EP0408069A2 (en) * 1989-07-14 1991-01-16 Union Carbide Chemicals And Plastics Company, Inc. Emulsions comprising aminopolysaccharides
WO1993018763A1 (en) * 1992-03-18 1993-09-30 U.S. Bioscience, Inc. Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
WO1997013528A1 (en) * 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
WO1998052585A1 (en) * 1997-05-23 1998-11-26 Lorus Therapeutics Inc. Immunomodulating, bile-derivable compositions for the treatment of viral disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017282A1 (en) * 1996-10-23 1998-04-30 Vertex Pharmaceuticals Incorporated Methods of using sucrose octasulfate to treat or prevent enveloped virus infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
EP0408069A2 (en) * 1989-07-14 1991-01-16 Union Carbide Chemicals And Plastics Company, Inc. Emulsions comprising aminopolysaccharides
WO1993018763A1 (en) * 1992-03-18 1993-09-30 U.S. Bioscience, Inc. Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
WO1997013528A1 (en) * 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
WO1998052585A1 (en) * 1997-05-23 1998-11-26 Lorus Therapeutics Inc. Immunomodulating, bile-derivable compositions for the treatment of viral disorders

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL-NISAIRAWI ET AL: "Antiviral activity of mixtures of compounds against herpes virus", ANTIVIRAL CHEMISTRY, vol. 1, no. 2, 1990, pages 125 - 129, XP000911081 *
ANDRONOVA: "Effect of 1-adamantan carboxylic acid amide (ACAA) and its combination with ribavirin ... combination of the inhibitors", ANTIBIOT. KHIMIOTER., vol. 42, no. 7, 1997, XP000997984 *
BRILLANTI, S. ET AL: "Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders", ITAL. J. GASTROENTEROL. HEPATOL. (1999), 31(2), 130-134, XP000997994 *
CHEMICAL ABSTRACTS, vol. 129, no. 6, 10 August 1998, Columbus, Ohio, US; abstract no. 62470, ANDRONOVA: "Effect of 1-adamantan carboxylic acid amide (ACAA) and its combination with ribavirin on experimental infection due to Sindbis virus i tissue culture and mouse brain. Study on possible isolation of the virus mutant resistant to ribavirin and combination of the inhibitors" XP002167914 *
MADREN, L. K. ET AL: "In vitro inhibitory effects of combinations of anti-influenza agents", ANTIVIRAL CHEM. CHEMOTHER. (1995), 6(2), 109-13, XP000997992 *
PANCHEVA ET AL: "Effect of Combined Acyclovir and Ribavirin on Experimental Herpes Simplex Virus Type I Keratoconjunctivitis in Rabbits", ACTA MICROBIOLOGICA BULGARICA, vol. 29, 1993, pages 61 - 64, XP000911006 *
See also references of EP1239923A2 *
YOUNOSSI, ZOBAIR M. ET AL: "The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C", SEMIN. LIVER DIS. (1999), 19(SUPPL. 1), 95-102, XP000997991 *

Also Published As

Publication number Publication date
WO2001045727A2 (en) 2001-06-28
EP1239923A2 (en) 2002-09-18
AU2012101A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
ES2620413T3 (en) Topical anthelmintic veterinary formulations
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
FR11C0017I2 (en) Use of spinosad or a formulation comprising spinosad
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
RU2002127804A (en) MEDICINAL SYSTEM FOR TREATMENT OF COMPLICATIONS CONNECTED WITH DIABETES AND NEUROPATHY, AND THEIR APPLICATION
JP2002526407A5 (en)
AU2108500A (en) Galenic formulation containing biotin
UA66812C2 (en) Drug formulation with controlled release of active ingredient
MXPA05005046A (en) Topical parasiticide formulations and methods of treatment.
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
MXPA05013270A (en) Transmucosal form of administration with reduced mucosal irritation.
EP1152002A4 (en) Pyrrole derivatives and cell death inhibitors
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent
BRPI0413474A (en) interferon and ribavirin use and kit for use in the treatment of viral infections
RU2002130719A (en) ACTIVATIVE COMPOSITION
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
DE60113807D1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF, WITH AN ANTIBIOTICUM AND AN EXPEKTORAN
CA2429793A1 (en) Interferon therapeutic effect enhancer
JP2002501901A5 (en)
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000983353

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000983353

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000983353

Country of ref document: EP